Cargando…
Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?
As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing breathlessness and fatigue even months after the onset of the disease. This overwhelming phenomenon has not been well defined and has been called “post-COVID syndrome” or “long-COVID...
Autores principales: | Bornstein, Stefan R., Voit-Bak, Karin, Donate, Timo, Rodionov, Roman N., Gainetdinov, Raul R., Tselmin, Sergey, Kanczkowski, Waldemar, Müller, Gregor M., Achleitner, Martin, Wang, Jun, Licinio, Julio, Bauer, Michael, Young, Allan H., Thuret, Sandrine, Bechmann, Nicole, Straube, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209771/ https://www.ncbi.nlm.nih.gov/pubmed/34140635 http://dx.doi.org/10.1038/s41380-021-01148-4 |
Ejemplares similares
-
Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis
por: Achleitner, Martin, et al.
Publicado: (2023) -
Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
por: Julius, Ulrich, et al.
Publicado: (2020) -
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis
por: Steenblock, Charlotte, et al.
Publicado: (2020) -
Therapeutic Apheresis in Metabolic Syndrome
por: Voinov, V.A.
Publicado: (2018) -
Current view: indications for extracorporeal lipid apheresis treatment
por: Schettler, Volker, et al.
Publicado: (2012)